Cardiac Insulin Resistance in Subjects With Metabolic Syndrome Traits and Early Subclinical Atherosclerosis.
Journal
Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975
Informations de publication
Date de publication:
01 11 2023
01 11 2023
Historique:
received:
15
05
2023
accepted:
23
08
2023
medline:
30
10
2023
pubmed:
15
9
2023
entrez:
15
9
2023
Statut:
ppublish
Résumé
Experimental evidence suggests that metabolic syndrome (MetS) is associated with changes in cardiac metabolism. Whether this association occurs in humans is unknown. 821 asymptomatic individuals from the Progression of Early Subclinical Atherosclerosis (PESA) study (50.6 [46.9-53.6] years, 83.7% male) underwent two whole-body 18F-fluorodeoxyglucose positron emission tomography-magnetic resonance (18F-FDG PET-MR) 4.8 ± 0.6 years apart. Presence of myocardial 18F-FDG uptake was evaluated qualitatively and quantitatively. No myocardial uptake was grade 0, while positive uptake was classified in grades 1-3 according to target-to-background ratio tertiles. One hundred fifty-six participants (19.0%) showed no myocardial 18F-FDG uptake, and this was significantly associated with higher prevalence of MetS (29.0% vs. 13.9%, P < 0.001), hypertension (29.0% vs. 18.0%, P = 0.002), and diabetes (11.0% vs. 3.2%, P < 0.001), and with higher insulin resistance index (HOMA-IR, 1.64% vs. 1.23%, P < 0.001). Absence of myocardial uptake was associated with higher prevalence of early atherosclerosis (i.e., arterial 18F-FDG uptake, P = 0.004). On follow-up, the associations between myocardial 18F-FDG uptake and risk factors were replicated, and MetS was more frequent in the group without myocardial uptake. The increase in HOMA-IR was associated with a progressive decrease in myocardial uptake (P < 0.001). In 82% of subjects, the categorization according to presence/absence of myocardial 18F-FDG uptake did not change between baseline and follow-up. MetS regression on follow-up was associated with a significant (P < 0.001) increase in myocardial uptake. Apparently healthy individuals without cardiac 18F-FDG uptake have higher HOMA-IR and higher prevalence of MetS traits, cardiovascular risk factors, and early atherosclerosis. An improvement in cardiometabolic profile is associated with the recovery of myocardial 18F-FDG uptake at follow-up.
Identifiants
pubmed: 37713581
pii: 153639
doi: 10.2337/dc23-0871
pmc: PMC10632182
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Radiopharmaceuticals
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2050-2057Informations de copyright
© 2023 by the American Diabetes Association.
Références
Curr Pharm Des. 2013;19(27):4806-17
pubmed: 23323621
JACC Cardiovasc Imaging. 2022 Jan;15(1):108-120
pubmed: 34274283
J Mol Cell Cardiol. 2015 Aug;85:104-16
pubmed: 26004364
J Nucl Cardiol. 2018 Feb;25(1):169-176
pubmed: 27473218
Eur Heart J. 2022 May 14;43(19):1809-1828
pubmed: 35567559
J Am Coll Cardiol. 2019 Apr 2;73(12):1371-1382
pubmed: 30922468
Am Heart J. 2013 Dec;166(6):990-8
pubmed: 24268213
Clin Nucl Med. 2017 Feb;42(2):88-94
pubmed: 27922863
Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):369-83
pubmed: 24271038
J Thorac Imaging. 2012 Jul;27(4):263-8
pubmed: 21629130
J Nucl Med. 2007 Oct;48(10):1662-9
pubmed: 17873124
Cardiovasc Diabetol. 2023 Jan 9;22(1):4
pubmed: 36624469
J Am Coll Cardiol. 2020 Oct 13;76(15):1723-1733
pubmed: 33032733
Am J Nucl Med Mol Imaging. 2014 Jun 07;4(4):346-53
pubmed: 24982820
Curr Probl Cardiol. 1994 Feb;19(2):59-113
pubmed: 8174388
Diabetes Care. 2021 May;44(5):e82-e84
pubmed: 33972315
Circulation. 2022 Oct 11;146(15):1189-1191
pubmed: 36214134
J Hypertens. 2016 Sep;34(9):1846-53
pubmed: 27367264
J Nucl Cardiol. 2000 May-Jun;7(3):242-8
pubmed: 10888395
Cardiovasc Diabetol. 2015 Nov 04;14:148
pubmed: 26538247
Sci Rep. 2020 Feb 26;10(1):3483
pubmed: 32103083
BMC Cardiovasc Disord. 2018 Oct 29;18(1):203
pubmed: 30373519
Circ Cardiovasc Imaging. 2010 Mar;3(2):211-22
pubmed: 20233863
J Mol Med (Berl). 2010 Oct;88(10):993-1001
pubmed: 20725711
PLoS One. 2020 Jan 29;15(1):e0228115
pubmed: 31995605
Lancet. 2011 Oct 29;378(9802):1547-59
pubmed: 21908036
Eur J Nucl Med Mol Imaging. 2005 Jan;32(1):98-101
pubmed: 15605289
Diabetes Care. 2010 Nov;33(11):2457-61
pubmed: 20699434
Diabetologia. 2007 Sep;50(9):1938-1948
pubmed: 17639306
Ann Nucl Med. 2014 Jul;28(6):505-11
pubmed: 24652347
J Am Coll Cardiol. 2021 Jul 13;78(2):156-179
pubmed: 34238438
F1000Prime Rep. 2014 Oct 01;6:90
pubmed: 25374668
Circulation. 2015 Jun 16;131(24):2104-13
pubmed: 25882487
Front Cardiovasc Med. 2022 Jun 29;9:924787
pubmed: 35845046
Diabetes. 2002 Oct;51(10):3020-4
pubmed: 12351442
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
J Clin Med. 2019 Jul 17;8(7):
pubmed: 31319598
J Am Coll Cardiol. 2021 Feb 23;77(7):888-898
pubmed: 33602472
Am J Physiol Endocrinol Metab. 2010 May;298(5):E1049-57
pubmed: 20159856